Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

U.S. President Donald Trump announced at a cabinet meeting at the White House on the 8th (local time) that he would impose ...

The denosumab biosimilars Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) are now available in the US.

Shares started a tad lower Wednesday on U.S. President Donald Trump's renewed tariff threats on copper and pharmaceuticals.

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Tam Jai International Co. Limited ('TJI' or the 'Company', together with its subsidiaries, the 'Group'; HKEX stock code: 2217), one of the leading and renowned restaurant groups in Hong Kong, has been ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...